Publications

Journal Papers

Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C
British Journal of Dermatology
August 2018 (accepted publication – online only) Link to Publication

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group
British Journal of Dermatology
August 2018 Link to Publication

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.
Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A et al
Human Molecular Genetics
November 2017  Link to Publication

Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength.
Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L, BADBIR and PSORT study groups.
Journal of Investigative Dermatology
November 2017 (Epub)  Link to publication

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.
Bowes J, Ashcroft J, Dand N, Jalali-najafabadi F, Bellou E, Ho P et al.
Annals of the Rheumatic Diseases
October 2017  Link to Publication

Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.
Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD et al.
British Journal of Dermatology
September 2017   Link to publication

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology.
Foulkes AC, Watson DS, Griffiths CEM, Warren RB, Huber W, Barnes MR
Journal of Investigative Dermatology
September 2017  Link to Publication

Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.
Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M et al.
Nature Communications
May 2017  Link to Publication

Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery.
Jia Z, Liu Y, Guan N, Bo X, Luo Z, Barnes MR.
BMC Genomics
May 2016  Link to Publication

Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy
Griffiths CE, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, et al.
Journal of Investigative Dermatology
December 2015  Link to publication

Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci.
Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, et al.
Nature Communications
May 2015  Link to publication

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
Bloem K, van LA, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, et al
Journal of Immunological Methods
March 2015  Link to Publication

Oral presentations
  • Psoriasis Stratification to Optimise Relevant Therapy (PSORT): Clinical and demographic predictors of biologic response for psoriasis.  RB Warren, AD Burden, B Tomenson, M Soliman R Emsley, CEM Griffiths, CH Smith; European Society for Dermatological Research 46th Annual Meeting (Munich);  September 2016
  • Patient stratification in psoriasis using large-scale patient-level data.  Nophar Geifman on behalf of the PSORT Consortium; Informatics for Health 2017 Conference (Manchester); April 2017
  • Personalising adalimumab treatment for patients with psoriasis: a UK, multi-centre, longitudinal, observational cohort study.  Nina Wilkinson on behalf of the PSORT Consortium;  97th Annual Meeting of the British Association of Dermatologists (Liverpool); July 2017 
  • Functional immunophenotyping analysis reveals adalimumab-induced impairment of TNF signalling in lymphoid cells in psoriasis.  Rosa Andres Ejarque on behalf of the PSORT Consortium;  Psoriasis: From Gene to Clinic 8th International Congress (London); December 2017
  • Genetic variation contributes to response to biologics: initial findings of the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium.    Nick Dand on behalf of the PSORT Consortium;  Psoriasis: From Gene to Clinic 8th International Congress (London); December 2017
  • Developing a therapeutic range and predicting response to biologics in patients with psoriasis: a multicentre prospective observational cohort study.  Teresa Tsakok, on behalf of the PSORT Consortium; Psoriasis: From Gene to Clinic 8th International Congress (London); December 2017
  • Anger expression and suppression: A large-scale multi-site study of people with psoriasis.  Rachael Jane Thorneloe on behalf of the PSORT Consortium;  13th UK Society for Behavioural Medicine Meeting, Liverpool; December 2017
  • Anti-drug antibodies in psoriasis patients during the first year of treatment with adalimumab/ustekinumab: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium;  98th Annual Meeting of the British Association of Dermatologists (Edinburgh); July 2018
  • Identifying adalimumab cellular and molecular targets in psoriasis.  Rosa Andres Ejarque on behalf of the PSORT Consortium;  7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • HLA genes associate with response to multiple biologic therapies in psoriasis.  Nick Dand on behalf of the PSORT Consortium;  7th International Investigative Dermatology (IID) Meeting (Orlando);  May 2018
  • Predicting response to ustekinumab in patients with psoriasis: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium, 7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • Anti-drug antibodies in psoriasis patients during the first year of treatment with adalimumab or ustekinumab: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium;  7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • Predicting response to ustekinumab in patients with psoriasis: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium;  98th Annual Meeting of the British Association of Dermatologists (Edinburgh); July 2018
  • Functional immunomonitoring via Imaging flow cytometry investigates the molecular effect of adalimumab and ustekinumab in psoriasis.  Rosa Andres Ejarque on behalf of the PSORT Consortium:  2018 British Society for Investigative Dermatology Annual Meeting (BSID) [London]; March 2018
  • Patient stratification using longitudinal data – application of latent class mixed models. Nophar Geifman; Medical Informatics Europe;  April 2018
Poster presentations
  • Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength.  Rachael Jane Thorneloe on behalf of the PSORT Consortium: Psoriasis: From Gene to Clinic 8th International Congress (London); December 2017
  • Beliefs about illness and medication are associated with psychological distress in patients using conventional systemic and biologic therapies for psoriasis.  Rachael Jane Thorneloe on behalf of the PSORT Consortium; Psoriasis: From Gene to Clinic 8th International Congress (London); December 2017
  • Identifying adalimumab cellular and molecular targets in psoriasis.  Rosa Andres Ejarque on behalf of the PSORT Consortium; 7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • HLA genes associate with response to multiple biologic therapies in psoriasis.  Nick Dand on behalf of the PSORT Consortium; 7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • Predicting response to ustekinumab in patients with psoriasis: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium; 7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • Anti-drug antibodies in psoriasis patients during the first year of treatment with adalimumab or ustekinumab: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium;  7th International Investigative Dermatology (IID) Meeting (Orlando); May 2018
  • Psoriasis Stratification to Optimise Relevant Therapy (PSORT): Genome-wide study reveals genetic drivers of response to biologic therapy in psoriasis.  Nick Dand on behalf of the PSORT Consortium;  47th Annual European Society for Dermatological Research Meeting (Austria); September 2018
  • Developing a therapeutic range and predicting response to biologics in patients with psoriasis: a multicentre prospective observational cohort study.  Teresa Tsakok on behalf of the PSORT Consortium: 47th Annual European Society for Dermatological Research Meeting (Austria);  September 2018
  • Patient stratification using longitudinal data – application of latent class mixed models.   Nophar Geifman; Medical Informatics Europe (Sweden);  April 2018